UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Front-line therapy of advanced ovarian cancer: new approaches

Ledermann, JA; (2017) Front-line therapy of advanced ovarian cancer: new approaches. Annals of Oncology , 28 (Suppl. 8) viii46-viii50. 10.1093/annonc/mdx452. Green open access

[thumbnail of Ledermann Valencia- Firstline treatment-FINAL-CLEAN.pdf]
Preview
Text
Ledermann Valencia- Firstline treatment-FINAL-CLEAN.pdf - Accepted Version

Download (230kB) | Preview

Abstract

BACKGROUND: The 5-year survival of ovarian cancer has slowly increased but to date much of this has been due to the use of more lines of treatment rather than better first-line therapy. In this setting, there has been little improvement over the past 15 years. The introduction of new treatments to extend time to first progression and overall survival remains a key objective of clinical research. DESIGN: The focus of research in the previous decade has been on the incorporation of anti-angiogenic therapy or dose-dense scheduling of paclitaxel (Taxol) to improve outcome. The new trials being conducted build on the knowledge gained and are focussing on two new areas of research, the use of PARP (poly-ADP ribose polymerase) inhibitors and immunotherapy. RESULTS: Ongoing randomised trials using PARP inhibitors or immune checkpoint inhibits are reviewed and the potential benefits and challenges of using these agents are discussed. CONCLUSIONS: Improvements in outcome from some of the many open trials may present challenges; interpretation of the outcome data needs to be taken in the context of clinical benefit and a health-economic assessment. The latter is becoming ever-more important as the cost of trials with combinations of targeted therapy is very great.

Type: Article
Title: Front-line therapy of advanced ovarian cancer: new approaches
Location: Valencia, SPAIN
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/annonc/mdx452
Publisher version: https://doi.org/10.1093/annonc/mdx452
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: Science & Technology, Life Sciences & Biomedicine, Oncology, ovarian cancer, first-line chemotherapy, anti-angiogenesis, PARP inhibitors, immunotherapy, Maintenance Therapy, Phase-3 Trial, Randomized Phase-2, Fallopian-Tube, Open-Label, Bevacizumab, Paclitaxel, Olaparib, Safety, Chemotherapy
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre
URI: https://discovery.ucl.ac.uk/id/eprint/10045817
Downloads since deposit
66Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item